Gene: TRAF3IP2

10758
ACT1|C6orf2|C6orf4|C6orf5|C6orf6|CANDF8|CIKS|PSORS13
TRAF3 interacting protein 2
protein-coding
6q21
Ensembl:ENSG00000056972 MIM:607043 Vega:OTTHUMG00000015379 UniprotKB:O43734
NG_032030.1
PubMed
0   ANCO-SNPs
CD|ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.123e-1 (AD)  6.383e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TMBIM10.91
LRP100.882
ABHD40.882
TTC380.877
SLC44A30.865
CNN30.863
AGTRAP0.862
MGST10.858
PTTG1IP0.855
TGIF10.855

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ABCC12-0.603
LHX6-0.594
CNTN6-0.589
CALHM1-0.587
ADRA1D-0.585
PPEF1-0.585
NXPH2-0.582
NEUROD6-0.578
ZNF385D-0.575
TYRP1-0.563

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRAF3IP2 mRNA"27188386
C0275764-hydroxy-2-nonenal4-hydroxy-2-nonenal results in decreased expression of TRAF3IP2 mRNA19191707
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRAF3IP2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of TRAF3IP2 mRNA21420995
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of TRAF3IP2 gene27153756
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of TRAF3IP2 mRNA24449571
C006632arsenic trioxidearsenic trioxide results in increased expression of TRAF3IP2 mRNA15761015
C006780bisphenol Abisphenol A results in increased expression of TRAF3IP2 mRNA25181051
C584509C646 compoundC646 compound results in increased expression of TRAF3IP2 mRNA26191083
C039671ciglitazone[ciglitazone binds to PPARG protein alternative form] which results in increased expression of TRAF3IP2 mRNA16197558
D019327Copper SulfateCopper Sulfate results in decreased expression of TRAF3IP2 mRNA19549813
D016572CyclosporineCyclosporine results in increased expression of TRAF3IP2 mRNA25562108
C014347decitabinedecitabine affects the expression of TRAF3IP2 mRNA23300844
D002945CisplatinCisplatin affects the expression of TRAF3IP2 mRNA23300844
D002945CisplatinCisplatin results in increased expression of TRAF3IP2 mRNA27392435
D002945Cisplatin[Piroxicam co-treated with Cisplatin] results in decreased expression of TRAF3IP2 mRNA21858171
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of TRAF3IP2 mRNA26924002
C024629dimethyl phthalatedimethyl phthalate affects the expression of TRAF3IP2 mRNA26924002
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAF3IP2 mRNA22079256
D000431EthanolEthanol results in increased expression of TRAF3IP2 mRNA19167417
D017313FenretinideFenretinide results in increased expression of TRAF3IP2 mRNA28973697
C492448ICG 001ICG 001 results in increased expression of TRAF3IP2 mRNA26191083
C016517indole-3-carbinolindole-3-carbinol affects the expression of TRAF3IP2 mRNA21396975
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF3IP2 mRNA25613284
D007854LeadLead results in decreased expression of TRAF3IP2 mRNA19921347
D008070LipopolysaccharidesLipopolysaccharides results in increased expression of TRAF3IP2 mRNA25613284
C517284monomethyl phthalatemonomethyl phthalate affects the expression of TRAF3IP2 mRNA26924002
C017096n-butoxyethanoln-butoxyethanol results in decreased expression of TRAF3IP2 mRNA19812364
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of TRAF3IP2 mRNA25729387
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of TRAF3IP2 mRNA19710929
C006253pirinixic acidpirinixic acid results in decreased expression of TRAF3IP2 mRNA17426115
C006253pirinixic acidpirinixic acid results in decreased expression of TRAF3IP2 mRNA19162173
D010894Piroxicam[Piroxicam co-treated with Cisplatin] results in decreased expression of TRAF3IP2 mRNA21858171
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of TRAF3IP2 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in decreased expression of TRAF3IP2 mRNA22079256
D011441PropylthiouracilPropylthiouracil results in decreased expression of TRAF3IP2 mRNA24780913
D020849Raloxifene Hydrochloride[Raloxifene Hydrochloride co-treated with ESR2 protein] results in decreased expression of TRAF3IP2 mRNA19059307
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of TRAF3IP2 mRNA23806026
D013629Tamoxifen[Tamoxifen co-treated with ESR2 protein] results in decreased expression of TRAF3IP2 mRNA19059307
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of TRAF3IP2 mRNA22298810
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF3IP2 mRNA25613284
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of TRAF3IP2 mRNA25729387
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRAF3IP2 mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of TRAF3IP2 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased methylation of TRAF3IP2 gene29154799
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of TRAF3IP2 gene25560391
D001335Vehicle EmissionsVehicle Emissions analog results in increased expression of TRAF3IP2 mRNA15541757
D024483Vitamin K 3Vitamin K 3 affects the expression of TRAF3IP2 mRNA20044591

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005102signaling receptor binding-IEA-  
GO:0005515protein binding-IPI12459498  21516116  25416956  
GO ID GO Term Qualifier Evidence PubMed
GO:0001783B cell apoptotic process-IEA-  
GO:0002230positive regulation of defense response to virus by host-IDA23066157  
GO:0006959humoral immune response-IBA21873635  
GO:0006959humoral immune response-IEA-  
GO:0035556intracellular signal transduction-NAS10962033  
GO:0043123positive regulation of I-kappaB kinase/NF-kappaB signaling-IBA21873635  
GO:0043123positive regulation of I-kappaB kinase/NF-kappaB signaling-IEP12761501  
GO:0048305immunoglobulin secretion-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005575cellular_component-ND-  
GO:0005622intracellular-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26222413Identification of long noncoding RNAs dysregulated in the midbrain of human cocaine abusers. (2015 Oct)Bannon MJJ Neurochem
24005976Common variants of ZNF750, RPTOR and TRAF3IP2 genes and psoriasis risk. (2014 Apr)Debniak TArch Dermatol Res